The collaboration will support the development, expansion and commercialization of Voyager’s new CNS product pipeline. It will also include several gene therapy programs for Parkinson’s disease (PD), Friedreich’s
By using the company’s Biochronomer polymer-based drug delivery platform, HTX-011 releases the local anesthetic bupivacaine and the anti-inflammatory meloxicam over an extended period. The Phase I trial in
The submission is for treatment of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r), dosed once daily in patients with genotype 1 (GT1) HCV infection. The application is based on data from the Phase
Since 2012, GSK owned a minority stake in Glycovaxyn, which has developed a biological conjugation platform technology that could help in the development of new prophylactic and therapeutic
The company said that TZ101 could potentially transform hematopoietic stem cell transplantation by reducing patient morbidity and mortality from GVHD. GVHD is a serious, life-threating complication of stem
Under the deal, Accelovance will support Panacea’s clinical development strategies by providing scientific/medical and regulatory expertise. Additionally, Accelovance will also provide contract research organization (CRO) support through project
The exclusive license was received through an amendment to Lion’s previously granted, non-exclusive, worldwide license to certain NIH issued and pending patent applications for the use of TIL
PF582 is Pfenex’s biosimilar candidate to Genentech’s Lucentis (ranibizumab injection). As part of the deal, Pfenex will receive an upfront payment of $51m once the collaboration receives antitrust
The new agreement builds on an existing collaboration between the two parties, which resulted in a successful launch of Emtrix in Italy as well as the expansion to
The post-doctoral diabetes research program will be fully funded by Novo Nordisk. In this program, a total of 12 post-doctoral researchers will be offered a three-year grant to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.